

Nimodipine Capsules (marketed as Nimotop).

July 15, 2010

MedWatch Safety Alert. Rockville, MD: US Food and Drug Administration; January 1, 2006. https://psnet.ahrq.gov/issue/nimodipine-capsules-marketed-nimotop

This U.S. Food and Drug Administration alert reminds health care professionals that nimodipine should only be administered orally, and that intravenous or parenteral administration can cause serious adverse events.